Atlas Trials

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Clinical trial NCT06077773 · TERMINATED

Trial details

NCT number
NCT06077773
Sponsor
Escient Pharmaceuticals, Inc
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Spontaneous Urticaria
Start date
2023-09-25
Primary completion
2024-12-18
Enrollment
113

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.